Horizon CEO Tim Walbert (L) and Viela CEO Bing Yao
February 1, 2021 07:29 AM ESTUpdated 09:13 AM
Deals

Hori­zon nabs an­oth­er rare dis­ease pipeline for the port­fo­lio in $3B buy­out. And As­traZeneca — a fu­ture ri­val — is get­ting about $780M of that

John Carroll

Editor & Founder

Sev­en months af­ter scor­ing its first FDA ap­proval, As­traZeneca spin­off Viela is be­ing bought out for $3 bil­lion.

Hori­zon an­nounced this morn­ing that it is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

Tra­vere plans to seek ex­pand­ed la­bel for kid­ney drug de­spite failed tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times